1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow PRT3789: new trials by email Literature Review of PRT3789 trials Research Report on PRT3789
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT3789, pembrolizumab - Advanced Solid Tumor, Esophageal Cancer | Phase 2 | Terminated | Prelude Therapeutics Incorporated | 6 | 2025-06-03 | 2026-02-02 |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PRT3789, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | Prelude Therapeutics Incorporated | 135 | 2023-05-02 | 2025-10-16 |
Neoplasm Metastasis (2) · Esophageal Neoplasms (1)
Prelude Therapeutics Incorporated (2)
Spain (2) · United States (2) · France (1) · Netherlands (1) · Singapore (1)